Eintrag weiter verarbeiten
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , |
| In: | Blood, 131, 2018, 17, S. 1910-1919 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
O’Brien, Susan Furman, Richard R. Coutre, Steven Flinn, Ian W. Burger, Jan A. Blum, Kristie Sharman, Jeff Wierda, William Jones, Jeffrey Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Luan, Ying James, Danelle F. Chu, Alvina D. Byrd, John C. O’Brien, Susan Furman, Richard R. Coutre, Steven Flinn, Ian W. Burger, Jan A. Blum, Kristie Sharman, Jeff Wierda, William Jones, Jeffrey Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Luan, Ying James, Danelle F. Chu, Alvina D. Byrd, John C. |
|---|---|
| author |
O’Brien, Susan Furman, Richard R. Coutre, Steven Flinn, Ian W. Burger, Jan A. Blum, Kristie Sharman, Jeff Wierda, William Jones, Jeffrey Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Luan, Ying James, Danelle F. Chu, Alvina D. Byrd, John C. |
| spellingShingle |
O’Brien, Susan Furman, Richard R. Coutre, Steven Flinn, Ian W. Burger, Jan A. Blum, Kristie Sharman, Jeff Wierda, William Jones, Jeffrey Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Luan, Ying James, Danelle F. Chu, Alvina D. Byrd, John C. Blood Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience Cell Biology Hematology Immunology Biochemistry |
| author_sort |
o’brien, susan |
| spelling |
O’Brien, Susan Furman, Richard R. Coutre, Steven Flinn, Ian W. Burger, Jan A. Blum, Kristie Sharman, Jeff Wierda, William Jones, Jeffrey Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Luan, Ying James, Danelle F. Chu, Alvina D. Byrd, John C. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2017-10-810044 <jats:title>Key Points</jats:title> <jats:p>Our 5-year experience shows sustained single-agent efficacy of ibrutinib in CLL patients, with complete response rates increasing over time. Long-term ibrutinib was well tolerated with no new safety signals; rates of grade ≥3 cytopenias decreased with continued therapy.</jats:p> Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience Blood |
| doi_str_mv |
10.1182/blood-2017-10-810044 |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Biologie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE3LTEwLTgxMDA0NA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE3LTEwLTgxMDA0NA |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 |
| imprint |
American Society of Hematology, 2018 |
| imprint_str_mv |
American Society of Hematology, 2018 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
obrien2018singleagentibrutinibintreatmentnaiveandrelapsedrefractorychroniclymphocyticleukemiaa5yearexperience |
| publishDateSort |
2018 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_unstemmed |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_full |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_fullStr |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_full_unstemmed |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_short |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_sort |
single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2017-10-810044 |
| publishDate |
2018 |
| physical |
1910-1919 |
| description |
<jats:title>Key Points</jats:title>
<jats:p>Our 5-year experience shows sustained single-agent efficacy of ibrutinib in CLL patients, with complete response rates increasing over time. Long-term ibrutinib was well tolerated with no new safety signals; rates of grade ≥3 cytopenias decreased with continued therapy.</jats:p> |
| container_issue |
17 |
| container_start_page |
1910 |
| container_title |
Blood |
| container_volume |
131 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346215897104384 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:35:37.953Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Single-agent+ibrutinib+in+treatment-na%C3%AFve+and+relapsed%2Frefractory+chronic+lymphocytic+leukemia%3A+a+5-year+experience&rft.date=2018-04-26&genre=article&issn=1528-0020&volume=131&issue=17&spage=1910&epage=1919&pages=1910-1919&jtitle=Blood&atitle=Single-agent+ibrutinib+in+treatment-na%C3%AFve+and+relapsed%2Frefractory+chronic+lymphocytic+leukemia%3A+a+5-year+experience&aulast=Byrd&aufirst=John+C.&rft_id=info%3Adoi%2F10.1182%2Fblood-2017-10-810044&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346215897104384 |
| author | O’Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C. |
| author_facet | O’Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C., O’Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C. |
| author_sort | o’brien, susan |
| container_issue | 17 |
| container_start_page | 1910 |
| container_title | Blood |
| container_volume | 131 |
| description | <jats:title>Key Points</jats:title> <jats:p>Our 5-year experience shows sustained single-agent efficacy of ibrutinib in CLL patients, with complete response rates increasing over time. Long-term ibrutinib was well tolerated with no new safety signals; rates of grade ≥3 cytopenias decreased with continued therapy.</jats:p> |
| doi_str_mv | 10.1182/blood-2017-10-810044 |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Biologie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE3LTEwLTgxMDA0NA |
| imprint | American Society of Hematology, 2018 |
| imprint_str_mv | American Society of Hematology, 2018 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T17:35:37.953Z |
| match_str | obrien2018singleagentibrutinibintreatmentnaiveandrelapsedrefractorychroniclymphocyticleukemiaa5yearexperience |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 1910-1919 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | O’Brien, Susan Furman, Richard R. Coutre, Steven Flinn, Ian W. Burger, Jan A. Blum, Kristie Sharman, Jeff Wierda, William Jones, Jeffrey Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Luan, Ying James, Danelle F. Chu, Alvina D. Byrd, John C. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2017-10-810044 <jats:title>Key Points</jats:title> <jats:p>Our 5-year experience shows sustained single-agent efficacy of ibrutinib in CLL patients, with complete response rates increasing over time. Long-term ibrutinib was well tolerated with no new safety signals; rates of grade ≥3 cytopenias decreased with continued therapy.</jats:p> Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience Blood |
| spellingShingle | O’Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C., Blood, Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_full | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_fullStr | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_full_unstemmed | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_short | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_sort | single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| title_unstemmed | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2017-10-810044 |